Recombinant Non-immunogenic Staphylokinase VS Alteplase for Massive PE a Randomized Non-inferiority Trial
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Objective: to evaluate the efficacy and safety of the Recombinant Non-immunogenic
Staphylokinase with its single bolus administration in comparison with the bolus-infusion
administration of the Alteplase in patients with massive pulmonary embolism